Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Magnetar Financial LLC

Magnetar Financial LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,113 shares of the biopharmaceutical company’s stock after selling 1,964 shares during the period. Magnetar Financial LLC’s holdings in Amicus Therapeutics were worth $189,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Teacher Retirement System of Texas lifted its stake in shares of Amicus Therapeutics by 18.3% during the fourth quarter. Teacher Retirement System of Texas now owns 65,927 shares of the biopharmaceutical company’s stock worth $621,000 after buying an additional 10,218 shares during the period. Xponance Inc. lifted its position in Amicus Therapeutics by 11.9% during the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 2,249 shares during the period. Intech Investment Management LLC grew its stake in Amicus Therapeutics by 59.7% during the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock valued at $1,175,000 after purchasing an additional 46,633 shares during the last quarter. Thrivent Financial for Lutherans acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at about $104,000. Finally, Cibc World Markets Corp acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at about $259,000.

Analyst Ratings Changes

A number of equities research analysts recently commented on FOLD shares. Wells Fargo & Company dropped their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $9.01 on Monday. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 52 week low of $8.55 and a 52 week high of $12.65. The stock’s 50-day moving average price is $9.35 and its 200-day moving average price is $10.06. The stock has a market capitalization of $2.77 billion, a PE ratio of -50.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.